Nebivolol Crescent Pharma (Nebivolol Hydrochloride)

Nebivolol is a beta‑blocker that acts on the cardiovascular system to control high blood pressure.

• Essential hypertension: reduces systolic and diastolic pressure by decreasing heart rate and peripheral resistance.
• Stage 1 hypertension: helps achieve target blood pressure when lifestyle measures are insufficient.
• Stage 2 hypertension: provides additional blood‑pressure control in patients requiring more intensive therapy.

• Nebivolol selectively blocks β1‑adrenergic receptors on cardiac myocytes, lowering heart rate and contractility. In parallel, it stimulates endothelial nitric‑oxide synthase, causing nitric‑oxide‑mediated vasodilation that reduces peripheral vascular resistance, together resulting in lowered arterial pressure.

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate discomfort.
• Dizziness or light‑headedness, especially on standing.
• Fatigue or general tiredness.
• Nasal congestion or rhinorrhea.
• Peripheral edema: mild swelling of ankles or feet.
• Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Acute bronchospasm in patients with reactive airway disease.
• Hepatic dysfunction manifested by elevated liver enzymes.
• Allergic reactions such as rash, pruritus, or angio‑edema.
• Syncope or fainting episodes.
• Cardiogenic shock in extreme cases.

Before initiating Nebivolol, clinicians should evaluate patient‑specific risk factors and monitor therapy.

• Cardiovascular assessment: review heart rate, rhythm, and any history of heart block.
• Renal impairment: adjust monitoring if creatinine clearance is reduced.
• Hepatic disease: use caution in patients with liver dysfunction.
• Concomitant beta‑blockers: avoid additive effects that may cause excessive bradycardia.
• Pregnancy and lactation: prescribe only if benefits outweigh potential risks.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Nebivolol may interact with other medicines that affect heart rate, blood pressure, or drug metabolism.

Major Interactions (Avoid)

• Other beta‑blockers: risk of profound bradycardia and hypotension.
• Calcium‑channel blockers (verapamil, diltiazem): can increase plasma concentrations of nebivolol.
• Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may raise nebivolol levels.

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate antihypertensive effect, requiring blood‑pressure checks.
• ACE inhibitors or ARBs: combined therapy can enhance blood‑pressure lowering.
• NSAIDs: may blunt antihypertensive response.
• Antidiabetic agents: monitor glucose as beta‑blockade can mask hypoglycaemia signs.